Philipp is the co-head of the Burnet Institute Tuberculosis Elimination and Implementation Science Group. He is an infectious diseases specialist with more than 15 years of extensive clinical and public health experience, and over 10 years’ experience in the management of TB/HIV programs. He has worked as a TB/HIV advisor, and supported program implementation and research in a range of settings. He has worked with MDR TB programs across Tajikistan, Uzbekistan, India, Myanmar, Uganda, Swaziland and Zimbabwe. A current project is the TB Practecal Study.
The TB Practecal study is a phase two, phase three study that aims to improve the treatment of multidrug resistant tuberculosis by reducing the time and using shorter treatment and less toxic regiments. Trial sites have been established working in conjunction with national health ministry's and national TB programs in Uzbekistan, Belarus and South Africa. Using new drugs, bedaquiline, delamanid, and pretomamandid the treatment for TB lasts for 6 months and does not include injections. The Practecal study also carries out public outreach programs for tuberculosis and how the public can seek effective treatment.